Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...
After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.
Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...
Senseonics, a medtech manufacturer developing long-term, implantable continuous glucose monitoring (CGM) systems, and ...
Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.
Eversense has recently launched the "Make Me Shine" campaign, presenting two of its latest products: Eversense Intensive Roll Ons and Eversense Made My Day Collection Perfume Mists with improved ...
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use ...
With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE ...